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Abstract: Background: The purpose of this study was to investigate the relationship between
the expression of key degradative enzymes by chondrocytes and the microarchitectural and min-
eral properties of subchondral bone across different stages of cartilage degradation in human hip
osteoarthritis (OA). Methods: Osteochondral samples at different stages of cartilage degradation
were collected from 16 femoral heads with OA. Osteochondral samples with normal cartilage were
collected from seven femoral heads with osteoporosis. Microcomputed tomography was used for the
investigation of subchondral bone microarchitecture and mineral densities. Immunohistochemistry
was used to study the expression and distribution of MMP13 and ADAMTS4 in cartilage. Results: The
microarchitecture and mineral properties of the subchondral plate and trabecular bone in OA varied
with the severity of the degradation of the overlying cartilage. Chondrocytes expressing MMP13 and
ADAMTS4 are mainly located in the upper zone(s) of cartilage regardless of the histopathological
grades. The zonal expression of these enzymes in OA (i.e., the percentage of positive cells in the
superficial, middle, and deep zones), rather than their overall expression (the percentage of positive
cells in the full thickness of the cartilage), exhibited significant variation in relation to the severity
of cartilage degradation. The associations between the subchondral bone properties and zonal and
overall expression of these enzymes in the cartilage were generally weak or nonsignificant. Conclu-
sions: Phenotypic changes in chondrocytes and remodelling of subchondral bone proceed at different
rates throughout the process of cartilage degradation. Biological influences are more important for
cartilage degradation at early stages, while biomechanical damage to the compromised tissue may
outrun the phenotypic change of chondrocytes and is critical in the advanced stages.
Keywords: cartilage degradation; MMP13; ADAMTS4; subchondral bone remodelling; subchondral
bone microarchitecture; tissue mineral density
1. Introduction
Osteoarthritis (OA) is one of the most common musculoskeletal conditions in the
ageing population. It affects all components of a joint, including the cartilage, subchondral
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bone, and synovium [1]. OA causes joint pain and dysfunction, and is among the leading
causes of disability [2]. There are no disease-modifying reagents for OA and most of the
current treatments for OA are symptom-relieving.
The pathological mechanism(s) of OA is still unclear, but the interactions between
cartilage and subchondral bone may play a critical role. Subchondral bone provides me-
chanical support for cartilage, absorbing and distributing mechanical forces [3]. Meanwhile,
articular cartilage lubricates joint movements and prevents concentrated focal stress on
subchondral bone [4]. Changes in the biomechanical properties of either of these two tissue
types will inevitably affect the transmission of load to the other, which can be perceived by
chondrocytes and bone cells and transmitted into intracellular signals, disrupting normal
cell and matrix metabolism [5,6]. Chondrocytes and bone cells in OA may also exert
regulatory effects on each other through biochemical factors (e.g., cytokines and growth
factors), which can travel across the osteochondral junction via increased vascular channels
and microcracks [5,7].
The microarchitecture and mineralization of bone are not only the determinants of its
mechanical properties, but also reflect the remodelling activities of bone cells. Numerous
studies on animal OA models have shown that cartilage degradation is accompanied by
changes in the microarchitecture and/or mineralization of subchondral bone (reviewed
in [8,9]). Several previous studies on human knees and hips have shown that the microarchi-
tectural and mineral parameters of subchondral bone are closely associated with the local
severity of cartilage degradation in OA [10–16]. Cartilage degradation, represented by the
loss of matrix macromolecules, especially proteoglycans and type II collagen, is attributable
to the proteolytic activities of aggrecanases and collagenases [17]. However, it is not yet
clear to what extent these enzymes contribute to different stages of cartilage degradation
in OA [18,19] and how their expression by chondrocytes and distribution in cartilage may
be related to the microarchitectural and mineral properties of subchondral bone.
To our knowledge, few studies on animal models have examined subchondral bone
properties and the expression of degradative enzymes in cartilage simultaneously [20–23],
and to date there have been no studies in which the expression of degradative enzymes
by chondrocytes was directly related to the microarchitecture and mineralization of sub-
chondral bone in either human samples or animal models. Filling this knowledge gap may
provide novel insights into the mechanisms and relationship between cartilage destruction
and subchondral bone remodelling in OA; this is the aim of the current study. We first car-
ried out a detailed investigation of the expression of degradative enzymes by chondrocytes
and their in situ distribution at various stages of cartilage degradation in human hip OA,
and then examined how these features of cartilage are associated with the properties of
subchondral bone. We selected matrix metalloproteinase-13 (MMP13) and a disintegrin
and metalloproteinase with thrombospondin motifs-4 (ADAMTS4) as representatives of
collagenases and aggrecanases, respectively [17], and included samples from patients with
osteoporosis (OP) for comparison.
2. Materials and Methods
2.1. Patient Selection
Sixteen patients with hip OA (six females and 10 males, mean age 68.1 ± 8.0 years)
and seven patients with low-energy fracture of the hip due to OP (three females and four
males, age 69.7 ± 5.9 years) who underwent hip arthroplasty surgeries were recruited at
Southmead Hospital, Bristol, UK. Diagnosis of OA and OP was based on established guide-
lines [24,25]. Femoral heads excised during the surgeries were collected upon obtaining
written consent from patients, which was approved by the Health Research Authority, UK
(17/WS/0217, 2 November 2017). For the OA group, patients with rheumatoid arthritis,
avascular necrosis, and known history of hip infection or trauma were excluded. For the
OP group, patients who were on medications affecting bone metabolism or had secondary
OP due to prolonged use of corticosteroids were excluded. Inclusion of femoral specimens
also depended on a macroscopic evaluation of the articular surface, as described below.
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2.2. Macroscopic Evaluation and Osteochondral Plug Extraction
The articular surface of OA femoral heads was regionally divided according to the
macroscopic grading system of cartilage degradation reported in a recent publication [10].
Two immediately adjacent osteochondral plugs (50 pairs) with 4 mm diameter and ~10 mm
height were collected from each graded region depending on availability using a steel
hollow punch (Figure 1). The included regions ranged from Grade I (normal/comparatively
normal) to Grade IV (severe cartilage erosion). Grade V, in which cartilage was completely
depleted, was not included. For the OP group, femoral heads were included only when the
articular surface fell into the Grade I category, then two immediately adjacent osteochondral
plugs were extracted from the superior, anterior, and posterior sites (21 pairs).
 
−
Figure 1. Macroscopic and microscopic evaluation of cartilage degeneration, and cylindrical region of interest for microCT
analysis. Femoral specimens from patients with OP and OA are shown in the first panel. Images of the OA specimen
show the same sample viewed from different angles. Arrows point to anatomical sites in OP specimen and regions with
different macroscopic grades in OA specimen from which two immediately adjacent osteochondral plugs were extracted.
Microscopic grading of the undecalcified paraffin embedded osteochondral samples using tissue sections stained with
safranin O and fast green are shown in the second panel. The three-dimensional cylindrical primary region of interest of
subchondral bone for analysis of microarchitecture and mineral properties are shown in the bottom panel.
2.3. MicroCT Scanning
One set of the paired plugs was stored at −80 ◦C, until they were transported
to the collaborating lab (University of Sheffield) for microCT scanning. These plugs
were a subset of the samples used in a previous study and were scanned by Skyscan
1172 (Kontich, Belgium), as previously described [10]. Briefly, images with an isotropic
voxel size of 4.87 µm were acquired using the following scanning parameters: 50 KeV
voltage, 179 µA intensity, 1180 ms integration time, and 180◦ rotation. Beam-hardening
artifacts were reduced using a 0.5-mm aluminium filter. Three-dimensional reconstruction
of datasets was carried out by NRecon software (1.6.9.4, Skyscan). Two calcium hydroxya-
patite phantoms with known mineral densities (0.25 and 0.75 g/cm3) were scanned and
reconstructed under the same conditions.
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2.4. MicroCT Image Analysis
The CT Analyzer software (CTAn, 1.17.7.2, Skyscan) was used for image analysis.
Segmentation between bone and soft tissue/marrow was based on a global binarization
threshold. A preliminary cylindrical region of interest (ROI) with 3.0 mm diameter and
4.0 mm depth was chosen for the subchondral bone of each sample (Figure 1), which was
then separated into ROIs of subchondral plate and trabecular bone using a semi-automated
protocol, as described previously [10].
The following microarchitectural parameters of subchondral trabecular bone were
calculated by the CTAn according to established guidelines [26]: bone volume fraction
(BV/TV), specific bone surface (BS/BV), trabecular thickness (Tb.Th), trabecular number
(Tb.N), structural model index (SMI), and connectivity density (Conn.Dn). The thickness of
the subchondral plate (Pl.Th) was also calculated by applying the sphere-fitting method [26]
to the contour of the ROI of the subchondral plate.
Hydroxyapatite phantoms were used to define a linear densitometric calibration equa-
tion to convert the X-ray attenuation coefficient values into tissue mineral density (TMD).
TMD, which reflects the mean degree of bone matrix mineralization, was measured as
mineral content over the volume of bone tissue, excluding pores and marrow space [12,26].
TMD was calculated for the subchondral plate (Pl.TMD) and trabecular bone (Tb.TMD).
2.5. Histological Processing and Microscopic Grading
The second set of paired plugs was fixed in formalin for 24 h immediately after extrac-
tion. The subchondral bone of these plugs was trimmed to about 1.0 mm in length without
damaging the overlying cartilage. They were then processed for paraffin embedding
without decalcification. Osteochondral tissue sections that were 7 µm thick were produced.
Duplicate sections randomly selected from each plug were subjected to safranin O-fast
green staining [27]. Microscopic grading of cartilage degradation was carried out using
a modified version [10] of the OARSI grading system [28] by two observers (Y. Li and
Y. Liem) in a blinded manner. Scoring was repeated after eight weeks and both inter- and
intra-observer intraclass correlation coefficients (ICCs) were above 0.94, demonstrating
excellent reliability [29,30]. Grades 5 and 6 were not present as samples with complete
cartilage loss were excluded from the study. Microscopic grades of these samples were
compared with those of the paired plugs scanned by microCT, as reported in [10], to make
sure the microscopic grade was the same between the paired adjacent plugs collected from
each macroscopically graded region.
2.6. Immunohistochemical Detection of MMP13 and ADAMTS4
Paraffin-embedded tissue sections were used to detect MMP13 and ADAMTS4 expres-
sion by chondrocytes using immunohistochemistry (IHC). Reagents were purchased from
Abcam (Cambridge, UK). Duplicated sections were deparaffinized and rehydrated. Then
heat-induced antigen retrieval was carried out in a citrate buffer at 95 ◦C for 10 min. This
was followed by blocking endogenous peroxidase activities with a 3% hydrogen peroxide
solution. Next, 10% normal goat serum (ab7481) was applied to tissue sections for 1 h
to prevent nonspecific antibody binding. Then polyclonal rabbit primary antibody (IgG)
against MMP13 (1:300, ab39012) or ADAMTS4 (1:200, ab84792) was applied and incubated
overnight at 4 ◦C. Additional sections were incubated with a blank buffer or with nonim-
mune rabbit IgG (ab37415) as negative control (Figure S1). The next day, sections were
washed and treated with biotinylated goat anti-rabbit secondary antibody (ab64256) for
30 min. This was followed by treatment with streptavidin–horseradish peroxidase (HRP)
conjugates (ab64269). Chromogenic detection was then carried out with diaminobenzidine
(DAB) chromogen and a substrate (ab64238), which produced brown precipitates in chon-
drocytes expressing ADAMTS4 and MMP13. Finally, sections were counterstained with
Harris haematoxylin.
Biomedicines 2021, 9, 1593 5 of 15
2.7. Measurement of MMP13 and ADAMTS4 Expression
Slides were observed and photographed with a DM5500 microscope and digital cam-
era (Leica Microsystems, Milton Keynes, UK). The number of chondrocytes positively and
negatively stained with MMP13 or ADAMTS4 was counted manually at 100× magnifi-
cation. A ROI was selected in the middle of sections with a width of 2 mm. The overall
expression was expressed as a percentage of positively stained cells through the full thick-
ness of cartilage in the ROI. The zonal expression was defined as the percentage of positive
cells in the superficial zone (SZ), middle zone (MZ), and deep zone (DZ), respectively.
Zones were differentiated according to characteristic chondrocyte morphology and align-
ment [4]. The availability of zones varied with the severity of cartilage degradation, i.e.,
SZ was lost and therefore not counted in microscopic Grade 3, and SZ and MZ were not
counted in Grade 4. The counting was repeated after eight weeks on 50 randomly selected
sections to evaluate intra-observer variability. The ICCs for the percentage of positively
stained cells were 0.906, 0.975, 0.943, and 0.954 for the SZ, MZ, DZ, and full thickness of
cartilage, respectively.
2.8. Statistical Analysis
Data are presented as the mean ± standard deviation (SD) unless otherwise indi-
cated. The normal distribution of data was inspected using the Shapiro–Wilk test. An
unpaired Student’s t-test and one-way ANOVA with a Bonferroni post hoc test were used
for parametric data. Mann–Whitney U (M–W) and Kruskal–Wallis (K–W) tests with Dunn’s
post hoc test were used for nonparametric data. Intragroup comparisons of proteinase
expression were made between the SZ, MZ, and DZ for OP and each grade of OA. In-
tergroup comparisons of subchondral bone properties and proteinase expression were
first made between different microscopic grades in the OA group to investigate variations
related to severity of cartilage degradation. Tests were then repeated to incorporate the OP
group to compare OP with different grades of OA. The associations between expression
of proteinases and subchondral bone properties in OP and OA were determined using
Pearson’s correlation for parametric data and Spearman’s correlation for nonparametric
data. Statistical significance was indicated by a two-tailed p-value less than 0.05. GraphPad
Prism (8.3.0, GraphPad Software, San Diego, CA, USA) and IBM SPSS (26.0, IBM Corp.,
Armonk, NY, USA) were used for statistical analysis and graphing.
3. Results
3.1. Microarchitecture and Mineral Properties of Subchondral Bone
Data for microarchitectural and mineral properties of subchondral bone in OA and
OP groups are summarized in Table 1 and presented in Figure 2. For microarchitecture,
within the OA group, the BV/TV, Tb.Th, Tb.N, and Conn.Dn of trabecular bone and
thickness of subchondral plate (Pl.Th) exhibited a statistically significant increasing trend
toward more severe degradation of the overlying cartilage (ANOVA p < 0.01 for BV/TV,
Tb.Th, Tb.N, and Pl.Th; K–W test; p < 0.001 for Conn.Dn). The values of these parameters
for OA Grade 1 and/or Grade 2 were significantly lower than those of Grades 3 and
4, as indicated by the post hoc analysis (Figure 2A–C,E,G). In contrast, SMI and BS/BV
displayed a significant decreasing trend with the increasing severity of OA (p < 0.001,
K–W test and ANOVA respectively), with Grades 1 and 2 showing significantly higher
values than Grades 3 and 4 (Figure 2D,F). As for the mineral properties, the TMD of
trabecular bone showed a decreasing trend with the increasing microscopic grade in OA
(ANOVA, p < 0.001; Bonferroni test, p < 0.001 for OA Grade 1 and 2 vs. Grade 3 and
4) (Figure 2H). However, the differences in TMD of the subchondral plate between OA
grades were not significant (Figure 2I). When compared between OP and different OA
microscopic grades, the microarchitectural and mineral properties of subchondral bone in
OP were similar to those in early stages of OA cartilage degradation (Grades 1 and 2), but
significantly different from those in advanced stages of cartilage degradation (Grades 3
and/or Grade 4) (Figure 2).
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Table 1. Microarchitecture and mineral densities of subchondral bone.






BV/TV (%) 25.64 ± 6.24 21.79 ± 9.12 24.95 ± 5.00 35.94 ± 6.53 39.17 ± 10.34 <0.001 <0.001
Tb.Th (mm) 0.18 ± 0.03 0.16 ± 0.03 0.17 ± 0.03 0.20 ± 0.03 0.22 ± 0.04 <0.001 <0.001
Tb.N (mm−1) 1.40 ± 0.27 1.35 ± 0.46 1.51 ± 0.31 1.72 ± 0.27 1.82 ± 0.29 0.004 <0.001
SMI (–) 1.31 ± 0.22 1.26 ± 0.43 1.20 ± 0.36 0.54 ± 0.52 −0.07 ± 1.34 <0.001 <0.001
Conn.Dn (mm−3) 2.25 ± 1.28 2.23 ± 1.18 3.26 ± 1.58 4.42 ± 1.87 5.82 ± 2.54 <0.001 <0.001
BS/BV (mm−1) 20.64 ± 3.46 23.35 ± 4.17 22.14 ± 3.48 18.02 ± 2.34 17.42 ± 3.52 <0.001 <0.001
Pl.Th (mm) 0.26 ± 0.04 0.29 ± 0.07 0.33 ± 0.07 0.40 ± 0.09 0.40 ± 0.10 0.003 <0.001
Tb.TMD (g/cm3) 1.41 ± 0.06 1.46 ± 0.11 1.41 ± 0.06 1.27 ± 0.07 1.23 ± 0.10 <0.001 <0.001
Pl.TMD (g/cm3) 1.22 ± 0.07 1.20 ± 0.10 1.16 ± 0.07 1.17 ± 0.07 1.15 ± 0.07 0.35 0.03
Values are mean ± SD. Analysis of variance (one-way ANOVA or Kruskal–Wallis test (SMI and Conn.Dn)) were first run between OA
grades to investigate variations in relation to the severity of cartilage degradation in OA. Then the tests were repeated to include the OP
group to compare OP with different OA grades.
Figure 2. Microarchitectural and mineral properties of subchondral bone in OP and different stages of cartilage degradation
in OA. (A) Volume fraction (BV/TV). (B) Trabecular thickness (Tb.Th). (C) Trabecular number (Tb.N). (D) Structural model
index (SMI). (E) Connectivity density (Conn.Dn). (F) Specific bone surface (BS/BV). (G) Subchondral plate thickness (Pl.Th).
(H) Tissue mineral density of trabecular bone (Tb.TMD). (I) Tissue mineral density of subchondral plate (Pl.TMD). The
boxplots show the median, interquartile range, and individual values of the parameters measured. Results of intergroup
comparisons between OA grades (statistical significance indicated by *) and between OP and OA grades (statistical
significance indicated by #) are shown, where * p < 0.05; ** p < 0.001; the same for #.
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3.2. Expression of MMP13 and ADAMTS4 by Chondrocytes
Overall and zonal expressions of MMP13 and ADAMTS4, represented by percentage
of positively stained chondrocytes in the full depth and in each zone of cartilage inde-
pendently, are summarized in Table 2 and illustrated in Figure 3. Results of intragroup
comparisons between SZ, MZ, and DZ are indicated in Table 2, and results of intergroup
comparisons between different OA grades and between OP and OA are indicated in
Figure 3. Representative images of staining are given in Figures 4 and 5.
Table 2. Summary of overall and zonal expression of MMP13 and ADAMTS4.
OP OA Grade 1 OA Grade 2 OA Grade 3 OA Grade 4
MMP13
Overall 22.76 ± 10.57 61.22 ± 8.29 61.53 ± 11.82 54.55 ± 8.99 53.17 ± 12.37
SZ 56.39 ± 19.62 88.64 ± 7.33 91.73 ± 4.64 / /
MZ 19.25 ± 16.11 ** 83.59 ± 10.35 80.22 ± 11.82 92.52 ± 6.34 /
DZ 4.45 ± 3.58 * 17.90 ± 8.67 ** 17.87 ± 12.55 ** 11.07 ± 6.26 ** 53.17 ± 12.37
ADAMTS4
Overall 21.12 ± 9.48 61.59 ± 6.06 62.37 ± 10.02 51.96 ± 10.97 53.86 ± 13.84
SZ 53.90 ± 17.34 88.48 ± 5.59 92.07 ± 6.26 / /
MZ 15.17 ± 12.96 ** 82.82 ± 7.68 78.97 ± 11.26 * 92.00 ± 7.76 /
DZ 3.93 ± 3.11 * 18.38 ± 7.48 ** 18.71 ± 11.52 ** 10.48 ± 5.46 ** 53.86 ± 13.84
Data are the percentage (mean ± SD) of positively stained chondrocytes. *Intragroup comparisons by post hoc tests (Bonferroni’s or
Dunn’s) following analysis of variance (one-way ANOVA or Kruskal–Wallis) for OP and OA Grades 1 and 2 (MZ vs. SZ and DZ vs. MZ),
and by Mann–Whitney U test for OA Grade 3 (DZ vs. MZ). * p < 0.05, ** p < 0.001. SZ, superficial zone; MZ, middle zone; DZ, deep zone.
Bonferroni’s or Dunn’s
– –
Figure 3. Overall and zonal expression of MMP13 and ADAMTS4 in OP and different stages of cartilage degradation in
OA. The box plots show the median, the interquartile range (IQR), and individual values of percentage of chondrocytes
stained positive for MMP13 (A,B) and ADAMTS4 (C,D). Results of intergroup comparisons between OA grades (statistical
significance indicated by *) and between OP and OA grades (statistical significance indicated by #) are shown for overall
expression (A,C) and zonal expression (B,D), respectively. * p < 0.05; ** p < 0.001; the same for #. SZ, superficial zone; MZ,
middle zone; DZ, deep zone.
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Figure 4. Representative images of IHC staining for MMP13 in OP and different stages of OA. The overall expression
through the full thickness of cartilage is presented in the first panel at 40× magnification. Lines indicate separation of
superficial (SZ), middle (MZ), and deep (DZ) zones and squares indicate higher-magnification (400×) areas in the subjacent
panels. Blue and red arrows point to typical negatively and positively stained cells, respectively.
 
Figure 5. Representative images of IHC staining for ADAMTS4 in OP and different stages of OA. The overall expression
through the full thickness of cartilage is presented in the first panel at 40× magnification. Lines indicate separation of
superficial (SZ), middle (MZ), and deep (DZ) zones and squares indicate higher-magnification (400×) areas in the subjacent
panels. Blue and red arrows point to typically negatively and positively stained cells, respectively.
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Within the OA group, there was no statistically significant difference in the overall
expression of MMP13 and ADAMTS4 by chondrocytes between different microscopic
grades of cartilage degradation (all around 60%; ANOVA, p > 0.05). The overall expression
of the two enzymes in all OA grades was significantly higher compared with the OP group
(Bonferroni test, p < 0.001) (Figure 3A,C).
In both OP and OA group, expression of MMP13 and ADAMTS4 was significantly
higher in the upper zone(s) (Table 2; Figure 3B,D). In the OP group, the percentage of chon-
drocytes expressing MMP13 and ADAMTS4 in the SZ (56.39 ± 19.62% and 53.90 ± 17.34%,
respectively) was significantly higher than that in the MZ (19.25 ± 16.11% and 15.17 ± 12.96%,
respectively) (Dunn’s test, p < 0.001), and the MZ had significantly higher values compared
to the DZ (4.45 ± 3.58% and 3.93 ± 3.11%, respectively) (Dunn’s test, p < 0.05). In OA
Grades 1 and 2, expression of MMP13 and ADAMTS4 in the DZ (around 18%) was signifi-
cantly lower compared to the MZ (around 80%) (Bonferroni test, p < 0.001), while there
was not a significant difference between MZ and SZ (around 90%), except for ADAMTS4
in Grade 2, the expression of which was significantly lower in the MZ compared with SZ
(Bonferroni test, p < 0.05). In OA Grade 3, the SZ was depleted and there were significantly
more chondrocytes expressing MMP13 and ADAMTS4 in the MZ (92.52 ± 6.34% and
92.00 ± 7.76%, respectively) compared to DZ (11.07 ± 6.26% and 10.48 ± 5.46, respectively)
(M–W test, p < 0.001). In OA Grade 4, SZ and MZ were not counted and 53.17 ± 12.37% and
53.86 ± 13.84% of chondrocytes expressed MMP13 and ADAMTS4 in the DZ, respectively.
Unlike the overall expression, the zonal expression of MMP13 and ADAMTS4 by chon-
drocytes exhibited significant variations in relation to the microscopic grades of cartilage
degradation in OA (Figure 3B,D). The expression of MMP13 in the MZ was significantly
higher in Grade 3 compared to Grade 2, and the expression of ADAMTS4 was signif-
icantly higher in Grade 3 compared to Grades 1 and 2 (Bonferroni test, p < 0.05). The
percentage of chondrocytes expressing MMP13 and ADAMTS4 in the DZ in Grade 4 was
significantly increased in contrast to those in Grades 1–3 (Bonferroni test, p < 0.001).
MMP13- and ADAMTS4-expressing chondrocytes in the SZ and MZ of OP cartilage
were significantly fewer compared to those in OA Grades 1, 2, and/or 3 (Bonferroni
test, p < 0.001) (Figure 3B,D). Similarly, the expression of the two enzymes in the DZ
was lower in OP compared with all grades of OA and was statistically significant for
Grades 1, 2, and 4 (Bonferroni test, p < 0.001) (Figure 3B,D).
3.3. Correlations between Expression of MMP13 and ADAMTS4 and Subchondral Bone Properties
Results of correlations between the expression of ADAMTS4 and MMP13 by chondro-
cytes and the microarchitectural and mineral properties of subchondral bone are summa-
rized in Table 3.
For the OP group, no statistically significant associations were found for either
ADAMTS4 or MMP13. For the OA group, a few subchondral bone parameters were found
to be significantly associated with either zonal or overall expression of the two enzymes,
but the correlations were generally weak, with a p-value just below 0.05 and correlation
coefficients around 0.3. Specifically, the overall expression of ADAMTS4 in OA cartilage
was significantly and negatively associated with BV/TV and Tb.Th, and positively with the
Tb.TMD (p = 0.049, 0.03, and 0.02; Pearson’s correlation coefficient = −0.28, −0.30, and 0.33,
respectively). The expression of MMP13 in the DZ of cartilage was significantly associ-
ated with BV/TV, Tb.Th, and Tb.TMD (p = 0.049, 0.03, and 0.02; Spearman’s correlation
coefficient = 0.28, 0.31, and −0.34, respectively). The overall expression of MMP13 in
full-thickness OA cartilage was associated with Conn.Dn of trabecular bone (p = 0.01;
Spearman’s correlation coefficient = −0.35).
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Table 3. Correlations between the expression of MMP13 and ADAMTS4 by chondrocytes and subchondral bone microarchi-
tecture and mineral densities.
OP OA
SZ MZ DZ Overall SZ MZ DZ Overall
MMP13
BV/TV 0.53 (−0.14) 0.19 (−0.30) 0.88 (0.04) 0.40 (−0.19) 0.06 (0.40) 0.17 (0.24) 0.049 (0.28) * 0.12 (−0.22)
Tb.Th 0.86 (−0.04) 0.56 (−0.13) 0.76 (0.07) 0.94 (0.02) 0.78 (0.06) 0.55 (0.10) 0.03 (0.31) * 0.14 (−0.21)
Tb.N 0.73 (−0.08) 0.20 (−0.29) 0.92 (0.02) 0.69 (−0.09) 0.10 (0.21) 0.17 (0.24) 0.55 (0.09) 0.14 (−0.21)
SMI 0.14 (0.34) 0.61 (0.12) 0.11 (0.36) 0.28 (0.25) 0.12 (−0.33) 0.30 (−0.31) 0.09 (−0.24) 0.2 (−0.18)
Conn.Dn 0.84 (0.05) 0.27 (−0.25) 0.35 (−0.22) 0.67 (−0.10) 0.10 (0.35) 0.86 (0.03) 0.11 (0.23) 0.01 (−0.35) *
BS/BV 0.54 (0.14) 0.36 (0.21) 0.99 (−0.00) 0.71 (0.08) 0.54 (−0.14) 0.37 (−0.16) 0.06 (−0.27) 0.14 (0.21)
Pl.Th 0.95 (−0.01) 0.16 (−0.32) 0.27 (−0.25) 0.60 (−0.12) 0.93 (−0.02) 0.87 (0.03) 0.37 (0.13) 0.20 (−0.18)
Tb.TMD 0.59 (0.13) 0.21 (0.29) 0.45 (0.17) 0.34 (0.22) 0.06 (−0.40) 0.06 (−0.32) 0.02 (−0.34) * 0.12 (0.22)
Pl.TMD 0.40 (−0.19) 0.78 (−0.07) 0.52 (0.15) 0.94 (−0.02) 0.47 (0.16) 0.96 (0.01) 0.51 (−0.10) 0.67 (0.06)
ADAMTS4
BV/TV 0.74 (−0.08) 0.09 (−0.38) 0.99 (0.003) 0.45 (−0.18) 0.24 (0.25) 0.20 (0.22) 0.12 (0.22) 0.049 (−0.28) *
Tb.Th 0.72 (−0.08) 0.98 (0.01) 0.09 (0.38) 0.64 (0.11) 0.35 (0.21) 0.06 (0.32) 0.10 (0.24) 0.03 (−0.30) *
Tb.N 0.98 (0.01) 0.30 (−0.28) 0.41 (−0.26) 0.23 (−0.28) 0.51 (0.14) 0.57 (0.10) 0.36 (0.13) 0.22 (−0.18)
SMI 0.30 (0.24) 0.22 (0.28) 0.13 (0.34) 0.41 (0.19) 0.54 (0.13) 0.16 (−0.24) 0.15 (−0.21) 0.08 (0.25)
Conn.Dn 0.91 (−0.02) 0.15 (−0.33) 0.50 (−0.16) 0.27 (−0.25) 0.06 (0.40) 0.52 (0.11) 0.19 (0.19) 0.15 (−0.21)
BS/BV 0.52 (0.15) 0.65 (0.11) 0.18 (−0.31) 0.93 (−0.02) 0.50 (−0.15) 0.05 (−0.33) 0.15 (−0.21) 0.06 (0.26)
Pl.Th 0.33 (0.22) 0.58 (−0.13) 0.73 (0.08) 0.63 (0.11) 0.28 (0.24) 0.17 (0.24) 0.18 (0.19) 0.67 (−0.06)
Tb.TMD 0.91 (0.03) 0.11 (0.36) 0.96 (0.01) 0.57 (0.13) 0.25 (−0.25) 0.21 (−0.22) 0.08 (−0.25) 0.02 (0.33) *
Pl.TMD 0.74 (−0.08) 0.78 (−0.06) 0.93 (−0.07) 0.84 (0.05) 0.31 (−0.22) 0.82 (−0.04) 0.05 (−0.28) 0.41 (−0.12)
Associations between expression of MMP13 and ADAMTS4 and subchondral bone properties were determined using Pearson’s cor-
relation or Spearman’s correlation (underlined). Data are given as p-values (correlation coefficients). Statistically significant results
are indicated by *.
4. Discussion
This is the first study in which the expression of the matrix-degrading proteinases by
chondrocytes and the microarchitectural and mineral properties of subchondral bone across
different stages of cartilage degradation have been studied concurrently in human OA
samples and the associations between these parameters investigated. The data showed that
chondrocytes expressing MMP13 and ADAMTS4 are mainly located in the upper zone(s) of
cartilage, regardless of the histopathological grades. Zonal expression of these enzymes in
OA, rather than their overall expression, exhibited a significant variation with the severity
of cartilage degradation. It was also shown that the associations between subchondral
bone properties and expression of these enzymes by chondrocytes were generally weak or
not significant in OA and OP samples.
Subchondral bone microarchitecture and TMD results are generally in agreement
with previous studies, showing that these parameters are closely associated with the
conditions of the overlying cartilage in OA [10–12]. A thicker subchondral plate and
volumetrically denser but hypomineralized trabecular bone were present in samples with
advanced cartilage degradation (microscopic Grades 3 and 4). The comparisons of OA
samples at various stages of cartilage degradation with OP samples support the notion
that subchondral bone remodelling in OA is a dynamic process that favours resorption at
early stages but is proformation, leading to sclerosis in late stages.
Moldovan et al. were among the first to report the localization of MMP13-expressing
chondrocytes in human OA cartilage [31]. Consistent with the current study, they showed
that the overall expression through the full thickness of cartilage was not significantly dif-
ferent between nonfibrillated and fibrillated regions. They also reported that the increased
production of MMP13 in OA mainly came from chondrocytes in the DZ and lower MZ,
and thus suggested that biological factors diffused from subchondral bone may be at least
partially responsible for the phenotypic changes of chondrocytes in OA. However, this
contrasts with the data presented here as well as in many other previous studies showing
that MMP13 production was mainly located in the upper zone(s) irrespective of whether
the sample had early or advanced cartilage degradation [32–34]. In addition, the steep
Biomedicines 2021, 9, 1593 11 of 15
drop in the percentage of positive cells from MZ to DZ in OA Grades 1–3 in this study
corresponds to the sharp transition shown by Wu et al. [33] between areas displaying
extensive staining and those with limited staining, suggesting a very slow progression
of the phenotypic change in the OA chondrocyte population [33], which will be further
discussed later.
Compared with MMP13, the localization of ADAMTS4 production in human OA
cartilage is more consistent in the literature, i.e., predominantly in the upper zone(s) [34–36],
as was shown by our study. This is in line with the universal observation that the loss of
proteoglycans is most significant at and near the articular surface across various stages of
OA, as demonstrated by the reduced cationic staining [28]. It is also worth noting that the
zonal distribution of ADAMTS4 production was similar to that of MMP13 (Figures 3–5),
supporting the suggestion that these two enzymes are co-expressed by the same group of
chondrocytes in OA [34], a group termed the “degradative chondrocytes” [34,36]. Such
co-expression can be further verified either by staining the consecutive tissue sections, or
by double antibody labelling. However, this is beyond the scope of the current study.
The findings that both ADAMTS4 and MMP13 are produced by chondrocytes located
in the upper zone(s) are supportive of the concept that cellular and biochemical alterations
in OA cartilage starts in the tissue closest to the articular surface [28,33]. With matrix
degradation advancing toward subchondral bone and with the increasing severity of carti-
lage damage, it was expected that chondrocytes in the deeper layers of cartilage would
become affected and exhibit the degradative phenotype [33,34,36] by starting to express
proteinases that are not seen or are at lower levels in healthy adult cartilage [37,38]. How-
ever, the data presented here show that chondrocytes in the DZ that were not expressing
MMP13 and ADAMTS4 in OA Grades 1 and 2 were still ‘clean’ of staining when matrix
loss progressed into the MZ (Grade 3). More surprisingly, even when matrix degradation
developed into the DZ (Grade 4) and there was just a thin layer of cartilage left, almost
half of the surviving chondrocytes, located mainly in the lower DZ next to subchondral
bone, were still negatively stained and displayed relatively normal morphology. In Grades
3 and 4, chondrocytes expressing MMP13 and ADAMTS4 increased in the MZ and DZ,
respectively, but the positively stained cells were located almost exclusively in clusters
near the surface and fissures (Figures 4 and 5). These observations explain why the overall
expression of the enzymes did not vary significantly between OA grades and may have
important implications.
First, a theoretical model of cartilage degradation in OA can be suggested. Initially,
the degradation of the extracellular matrix (ECM) is driven largely by the proteolysis
of macromolecules, as a result of the phenotypic change of chondrocytes in the upper
zones with increased production of cytokines, collagenase(s), and aggrecanase(s). Once
the ECM is compromised, cartilage loses its unique elastic and frictionless properties
and becomes more susceptible to mechanical destruction. The mechanical wear of the
cartilage with inferior quality advances toward deeper layers quickly, while the shift of
chondrocyte phenotype may be a much more gradual process [33]. At a certain stage of
progression (likely between Grades 2 and 3), the directly damaging effects of mechanical
forces may outrun those of biochemical disruption and reach the deeper layers of cartilage
before subjacent chondrocytes develop a degradative phenotype. Then, at the late stage
of cartilage degradation (Grade 4), erosion of the last portion of cartilage leading to the
exposure of subchondral bone (Grade 5) may be largely or purely mechanical rather than
biological. Several earlier studies have highlighted that cartilage degradation in OA is not
simply a consequence of ‘wear and tear’ but a condition resulting from both biological and
biomechanical reactions, with the former being more important [2,28,39–42]. The model
presented here is consistent with these previous studies but additionally suggests that the
relative contribution and importance of biological factors and mechanical disruptions to
cartilage degradation and matrix loss may vary at different stages.
Second, it seems that biochemical factors (e.g., growth factors and cytokines) that
induce a phenotypic change of chondrocytes are mainly produced by chondrocytes in the
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upper zones to act in an autocrine or paracrine manner, and/or from the synovium rather
than from subchondral bone. If this was not the case, then chondrocytes in the DZ, which
are closest to subchondral bone and are subjected to vascular invasion, should be affected
at least at some point in the degradation process. Another possibility is that chondrocytes
in the DZ may function as an intermediate of subchondral bone-derived signals rather than
a direct effector that produces enzymes to degrade the ECM.
Subchondral bone is important for the maintenance of cartilage physiology in normal
joints and contributes to cartilage pathology in disease conditions such as OA. It fulfils
such roles by affecting the distribution of load in the overlying cartilage and through the
cellular and biochemical crosstalk via the osteochondral junction. However, in this study, a
statistically significant correlation between cartilage enzyme expression (overall and zonal)
and subchondral bone microarchitectural and mineral properties was only observed for a
few of the parameters investigated and the associations were rather weak, with p-values
between 0.01 and 0.05 and correlation coefficients just around 0.3. This was unexpected
since both the zonal expression of MMP13 and ADAMTS4 by chondrocytes and the mi-
croarchitecture and mineralization of subchondral bone exhibited significant variations in
relation to the degree of cartilage damage (microscopic grading). One possible explanation
is that the efficiency of adaptation in response to various mechanical or biological stimuli is
markedly different between cartilage and bone [43–45]. Bone remodelling is a rapid process;
the duration of a typical remodelling cycle takes 3–6 months from osteoclast activation
to the completion of bone formation by osteoblasts [46]. On the contrary, the turnover
of cartilage matrix components, especially aggrecan and type II collagen, takes decades
in normal conditions, reflecting the limited capacity of chondrocytes to modify their sur-
rounding matrix [47]. Although the metabolic activities of chondrocytes are elevated in
OA, they are still relatively slow and the phenotype transition may take years [33,43].
Therefore, the pathological changes in subchondral bone and chondrocytes are likely to be
at a different pace throughout OA, despite the fact that they both contribute to cartilage
degradation. This is complementary to the cartilage degradation model suggested above:
the increased mechanical stress borne by cartilage, as a result of the rapidly deteriorating
subchondral bone properties, may outrun the biochemical degradation at some point and
erodes cartilage quickly before chondrocytes in the deeper areas can respond.
A limitation of this study is that two immediately adjacent osteochondral samples
from each of the regions graded by severity of cartilage degradation were used for microCT
scanning and IHC detection. Although we ensured that the paired samples had the same
macroscopic and microscopic grading, it would have been better if IHC were carried out
on the same samples scanned by microCT. In addition, the scanned samples went through
several freeze–thaw cycles as we did not have a microCT device on-site, which caused
detrimental effects on the histological quality and antigenicity of tissue. Moreover, this is
a cross-sectional study that used the severity of cartilage degradation (histopathological
grading) as an indication of different stages of OA [38]. The associations between subchon-
dral bone properties and expression of degradative enzymes by chondrocytes should also
be investigated in a longitudinal manner—for example, in animal models.
5. Conclusions
In conclusion, the microarchitectural and mineral properties of subchondral bone and
zonal expression, rather than overall expression, of MMP13 and ADAMTS4 by chondro-
cytes exhibited a significant variation in relation to the local severity of cartilage degradation
in OA. However, the associations between subchondral bone properties and expression of
these enzymes in cartilage were generally weak or not significant. Based on these findings,
as well as the characteristic distribution of proteinase-expressing chondrocytes, a theoret-
ical model of cartilage degradation in OA can be suggested: biochemical influences are
more important to ECM degradation at the initiation and early stages, while the mechanical
wear of the compromised tissue is faster than the phenotypic change of chondrocytes and
is critical in advanced stages.
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